Acumen Pharmaceuticals, Inc. (ABOS): Capital Expenditures

Annual figures by period end, from SEC filings.

$88.0K

Year ended 2025-12-31

Trailing 12 months to 2026-06-30

-18.2%

3-year compound annual growth

2021-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$88.0K	+450.0%	2026-03-26, From 2025-01-01
2024-12-31	$16.0K	-23.8%	2026-03-26, From 2024-01-01
2023-12-31	$21.0K	-87.0%	2025-03-27, From 2023-01-01
2022-12-31	$161.0K	+302.5%	2024-03-26, From 2022-01-01
2021-12-31	$40.0K	n/a	2023-03-27, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Acumen Pharmaceuticals, Inc. (ABOS)	2025-12-31	$88.0K	+450.0%
Kalaris Therapeutics, Inc. (KLRS)	2025-12-31	$200.0K	n/a
Candel Therapeutics, Inc. (CADL)	2025-12-31	$587.0K	n/m
Humacyte, Inc. (HUMA)	2025-12-31	$884.0K	-43.8%
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$99.0K	n/a
Artiva Biotherapeutics, Inc. (ARTV)	2025-12-31	$2.59M	+303.0%
Zura Bio Ltd (ZURA)	2025-12-31	$113.0K	+50.7%
Lineage Cell Therapeutics, Inc. (LCTX)	2025-12-31	$522.0K	-7.6%
Palisade Bio, Inc. (PALI)	2024-12-31	$0	-100.0%

Compare ABOS, KLRS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗